ArticleMikrochimica acta2025
Development of a molecularly imprinted electrochemical sensor for erlotinib detection using a modified screen-printed carbon electrode.
Article in Mikrochimica acta, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Titanium dioxide nanoparticle-modified screen-printed electrode for erlotinib determination.ADMET & DMPK · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A screen-printed carbon electrode (SPCE) based on a molecularly imprinted polymer (MIP) technique has been modified to provide detection of erlotinib (ERL). For this purpose, the pyrogallol (PG) monomer in the presence of ERL as an analyte has been electropolymerized on the SPCE surface. The introduced sensor has been characterized through differential pulse voltammetry (DPV), cyclic voltammetry (CV), and field emission scanning electron microscopy (FESEM) methods. The modified SPCE allowed ERL detection in a linear range of 0.05-800 nM with a limit of detection (LOD) of 0.016 nM. The applicability of modified SPCE was successfully investigated in serum samples. Lastly, for validation, sensor performance was compared with high-performance liquid chromatography (HPLC). The introduced sensor exhibited good application in the biomedical field.
Indexed as
Identifiers
39930278What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.